Recce Pharmaceuticals (RCE) investor relations material

Company overview and strategy

• Clinical-stage biotech developing a new class of synthetic anti-infectives with a unique mechanism of action targeting a broad spectrum of infections, including multidrug-resistant bacteria.

• Publicly traded on ASX and FSE, with a US presence and over 40 granted patents across major markets valid to 2041.

• Focused on addressing antibiotic resistance, with faster action than traditional antibiotics and efficacy against ESKAPE pathogens.

• Received US Defense Burn Research Program grant and US Army Medical Research Institute collaboration.

• RECCE® 327 granted QIDP designation by US FDA, providing 10 years of market exclusivity and fast-track approval.

Financials and capital structure

• Market capitalization of AUD $137.36 million, share price at AUD $0.4750, and 289.18 million shares on issue as of May 2026.

• Top 20 shareholders hold 57% of shares.

• Awarded up to AUD $85 million in Advanced Overseas Finding by the Australian Government, extending R&D rebates globally for three years.

Product pipeline and clinical progress

• Multiple clinical programs in Phase I, II, and III for indications such as sepsis, UTI/urosepsis, burn wounds, and ABSSSI, including diabetic foot infections.

• Registrational Phase 3 trial for R327 topical gel in Indonesia for diabetic foot infections, with interim data expected after 155 of 310 participants.

• Approval received from Indonesian authorities, with plans for ASEAN market entry and global registration strategy.

• Previous Phase I/II and II trials achieved all primary and secondary endpoints, demonstrating safety, tolerability, and efficacy.